Evidence map›Paper›PMID 30562068›Full record

Trial reportCirculation. Cardiovascular quality and outcomes2018

Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes.

Alexander C Fanaroff, Derek Cyr, Megan L Neely, Jeffery Bakal, Harvey D White, Keith A A Fox, Paul W Armstrong, Renato D Lopes, E Magnus Ohman, Matthew T Roe

2 registry-linked trialsAbstract readComparative StudyMulticenter StudyPragmatic Clinical Trial
In one paragraph

Trial report in Circulation. Cardiovascular quality and outcomes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
11.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00699998 phase3completednot on this map

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed

TypeinterventionalSponsorEli Lilly and CompanyRan2008 to 2012Enrolled9,326ConditionsAcute Coronary SyndromeArmsClopidogrel, Prasugrel, Commercially-available Aspirin
NCT05130268 phase4completednot on this mapstarted 2021, after this paper: background citation

Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation

TypeinterventionalSponsorAmerican Heart AssociationRan2021 to 2024Enrolled339ConditionsAtrial FibrillationArmsDronedarone
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Advancing patient-centered metrics for heart transplantation: The role of days alive and outside the hospital.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
  13. Article
  14. Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Article
  15. Article
  16. Patient-Centered Rocket Science: Accurate but Imprecise.Journal of the American Heart Association · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alexander C FanaroffDivision of Cardiology (A.C.F., R.D.L., E.M.O., M.T.R.), Duke University, Durham, NC.
Derek CyrDuke Clinical Research Institute (A.C.F., D.C., M.L.N., R.D.L., E.M.O., M.T.R.), Duke University, Durham, NC.
Megan L NeelyDuke Clinical Research Institute (A.C.F., D.C., M.L.N., R.D.L., E.M.O., M.T.R.), Duke University, Durham, NC.
Jeffery BakalDivision of Cardiology, University of Alberta and the Canadian VIGOUR Centre, Edmonton (J.B., P.W.A.).
Harvey D WhiteGreen Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, New Zealand (H.D.W.).
Keith A A FoxCentre for Cardiovascular Science, University of Edinburgh, United Kingdom (K.A.A.F.).
Paul W ArmstrongDivision of Cardiology, University of Alberta and the Canadian VIGOUR Centre, Edmonton (J.B., P.W.A.).
Renato D LopesDivision of Cardiology (A.C.F., R.D.L., E.M.O., M.T.R.), Duke University, Durham, NC.
E Magnus OhmanDivision of Cardiology (A.C.F., R.D.L., E.M.O., M.T.R.), Duke University, Durham, NC.
Matthew T RoeDivision of Cardiology (A.C.F., R.D.L., E.M.O., M.T.R.), Duke University, Durham, NC.
University of Edinburgh · GB

Funding

Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
NHLBI NIH HHS T32 HL069749
6 · The paper itself

Abstract

Background Cardiovascular clinical trials have traditionally incorporated separate time-to-first-event analyses for their primary efficacy and safety comparisons, but this framework has a number of limitations, including limited patient-centeredness and a traditional requirement for central adjudication. Days alive and out of the hospital (DAOH) has the potential to provide additional insight. Methods and Results TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) was a randomized, multinational clinical trial that compared the effect of prasugrel versus clopidogrel in patients stabilized after non-ST segment elevation acute coronary syndrome treated without revascularization; the trial had a neutral result. DAOH was calculated for each patient using site-submitted adverse event reporting data. We described patterns of DAOH overall, and among younger adults (<75 years old), older adults (≥75 years old), and frail/prefrail patients over 12 months follow-up and used Poisson regression to compare DAOH for patients randomized to prasugrel versus clopidogrel. Of 9249 patients in the overall trial population, 500 (5.4%) died, and 2504 (27.1%) were hospitalized 4150 times over 12 months' follow-up; the mean±SD DAOH was 317±86. The distribution of DAOH over 12 months was left-skewed, with median DAOH 363 days. Among younger adults, older adults, and frail/prefrail patients, mean DAOH were 323, 293, and 304 days, respectively. There were no differences in DAOH by treatment arm in the overall population (rate ratio, 1.00; 95% CI, 0.99-1.01) or any subgroup. Conclusions These results support the feasibility of determining DAOH, a patient-centered outcome that can potentially overcome many of the disadvantages of the traditional time-to-composite-event framework in the clinical trial setting. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT00699998.

Indexed as

HospitalizationAcute Coronary SyndromeAgedClopidogrelDouble-Blind MethodFeasibility StudiesFemaleHealth StatusHumansLength of StayMaleNon-ST Elevated Myocardial InfarctionPatient-Centered CarePlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor Antagonistsacute coronary syndromesclinical trialclopidogrelhospitalpatientsstroke

Identifiers

PMID30562068
PMCPMC6347414
OpenAlexW2903198138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.